All News

In today’s Pharmaceutical Executive Daily, Sanofi formally confirms its CEO leadership following a shareholder vote, US prescription drug spending is projected to surpass $1 trillion in 2026, and Inizio launches a next-generation hub services model aimed at simplifying patient access and support.

Inizio launches integrated hub services model to streamline patient access, reimbursement, and adherence, reflecting a broader industry shift toward data-driven, end-to-end patient support strategies.

A report from American Society of Health-System Pharmacists projects U.S. prescription drug spending to surpass $1T in 2026, driven largely by surging demand for GLP-1 weight-loss therapies.

Sanofi is appointing Belén Garijo chief as director and chief executive officer after its annual meeting, underscoring the company's leadership and governance changes.

RNA rewards companies that can integrate biology, data science, manufacturing, and clinical development into a single adaptive engine.

Jessica Lovett, VP of commercial strategy and innovation at Innomar, discusses the importance of meeting the needs of everyone at the table.

In the second part of his interview, Jeff Golfman notes how shelf-life constraints and shipping delays heighten drug shortage risk, prompting calls for diversified sourcing and larger inventory buffers.

Kaida Biopharma’s chair and acting CEO discusses how President Trump’s MFN policies and other regulatory actions are impacting pharma’s ability to invest in new treatments and adjusting international launch strategies.

In today's Pharmaceutical Executive Daily, Rocket Pharmaceuticals announces a $180 million sale of its rare pediatric disease priority review voucher, Teva Pharmaceutical enters a definitive agreement to acquire Emalex Biosciences for up to $900 million, and a feature article examines the pharmaceutical supply chain risks converging around the Strait of Hormuz.

Teva will acquire Emalex to add ecopipam, a late-stage pediatric Tourette syndrome candidate, ahead of a planned 2026 filing.

In an exclusive Q&A at Asembia’s AXS26 Summit, Syneos Health's vice president of strategic market access and patient support Kim Plesnarski touches on rapid digital innovation, evolving market structures, and shifting regulatory pressures.

Rocket Pharmaceuticals sells it's priority review voucher for $180M, securing non-dilutive funding to extend runway and advance gene therapy pipeline.

In the final part of her interview, Plesnarski notes how market access strategies evolve into core launch drivers as IRA timelines, pricing pressures, and digital adherence tools reshape how companies maximize value.

Dr. Stella Vnook explains how pharma pricing is likely to be impacted by various regulatory actions, such as MFN.

In the first part of his interview, Jeff Golfman, notes how The Strait of Hormuz disruption exposes broader global supply chain contraction, raising risks for vaccines, cancer therapies, and other critical medicines.

In today's Pharmaceutical Executive Daily, we cover Sun Pharma and IMG Pharma's respective acquisitions, FDA's approval of AstraZeneca's Breztri, and a new feature examining why Ireland has become one of the pharmaceutical industry's most strategically important global manufacturing hubs.

At Asembia AXS26, Clarivate’s Dee Chaudhary outlined how U.S. drug pricing policy is rapidly shifting, driving more aggressive payer utilization management, tightening access controls, and increasing volatility in pharmaceutical pricing and forecasting.

Jessica Lovett, VP of commercial strategy and innovation at Innomar, explains how handling uncertainty comes down to discipline.

Sun Pharma is set to acquire Organon in a $11.75 billion deal, while IMG Pharma enters a definitive agreement to purchase Matsumoto, signaling continued global consolidation and portfolio expansion across the pharmaceutical industry.

FDA approves Breztri Aerosphere for asthma, introducing the first single-inhaler triple-combination maintenance therapy for patients aged 12 and older.

In this exclusive video interview at Assembia 2026, Kim Plesnarski touches on how digital tools reshape patient access programs as real-time data and EMR integration drive more personalized, workflow-embedded support strategies.

Dr. Stella Vnook explains how US pricing regulations, such as MFN and the IRA, are forcing pharma companies to adjust strategies in international markets.

Ireland has built a track record of regulatory excellence that few regions have matched.

Experts convened for a panel discussing how tariffs and MFN policies are impacting drug pricing and what regulatory hurdles they face ahead of the midterms later this year.

Tommy Bramley, SVP of global consulting at Cencora, discusses how broadening acceptance of RWE has a broad impact on launch strategies.

In today's Pharmaceutical Executive Daily, Eli Lilly announces a definitive agreement to acquire Ajax Therapeutics for up to $2.3 billion, adding a first-in-class JAK2 inhibitor for blood cancers to its expanding oncology pipeline, the FDA approves a supplemental application for Johnson and Johnson's Caplyta backed by Phase III data showing a 63% reduction in relapse risk in adults with schizophrenia, and Pharmaceutical Executive speaks with Maher Masoud, CEO of MaxCyte, on moving cell and gene therapies toward commercial scale.

FDA approves Caplyta for relapse prevention in schizophrenia, adding long-term Phase III data showing a 63% reduction in relapse risk and reinforcing its role in sustained disease management.

Eli Lilly to acquire Ajax Therapeutics in up to $2.3B deal, adding a first-in-class Type II JAK2 inhibitor to strengthen its blood cancer pipeline.